Amgen Inc (AMGN)
294.52
+4.62
(+1.59%)
USD |
NASDAQ |
Nov 22, 16:00
294.53
+0.01
(+0.00%)
After-Hours: 20:00
Amgen Cash from Financing (Quarterly): -3.651B for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -3.651B |
| June 30, 2024 | -2.649B |
| March 31, 2024 | -1.708B |
| December 31, 2023 | 2.754B |
| September 30, 2023 | -2.005B |
| June 30, 2023 | -1.21B |
| March 31, 2023 | 21.51B |
| December 31, 2022 | -1.049B |
| September 30, 2022 | 1.588B |
| June 30, 2022 | -1.062B |
| March 31, 2022 | -3.514B |
| December 31, 2021 | -6.558B |
| September 30, 2021 | 2.848B |
| June 30, 2021 | -2.622B |
| March 31, 2021 | -1.939B |
| December 31, 2020 | -3.59B |
| September 30, 2020 | -1.798B |
| June 30, 2020 | 775.00M |
| March 31, 2020 | -254.00M |
| December 31, 2019 | -1.929B |
| September 30, 2019 | -2.859B |
| June 30, 2019 | -5.992B |
| March 31, 2019 | -4.987B |
| December 31, 2018 | -3.568B |
| September 30, 2018 | -2.58B |
| Date | Value |
|---|---|
| June 30, 2018 | -4.65B |
| March 31, 2018 | -11.69B |
| December 31, 2017 | -2.134B |
| September 30, 2017 | -1.107B |
| June 30, 2017 | -1.242B |
| March 31, 2017 | -2.111B |
| December 31, 2016 | -2.122B |
| September 30, 2016 | 582.00M |
| June 30, 2016 | -2.286B |
| March 31, 2016 | 1.227B |
| December 31, 2015 | -922.00M |
| September 30, 2015 | -1.458B |
| June 30, 2015 | 6.00M |
| March 31, 2015 | -1.397B |
| December 31, 2014 | -3.162B |
| September 30, 2014 | -513.00M |
| June 30, 2014 | 896.00M |
| March 31, 2014 | -495.00M |
| December 31, 2013 | 3.807B |
| September 30, 2013 | 2.787B |
| June 30, 2013 | -283.00M |
| March 31, 2013 | -3.585B |
| December 31, 2012 | -1.347B |
| September 30, 2012 | 1.424B |
| June 30, 2012 | 1.707B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-6.558B
Minimum
Dec 2021
21.51B
Maximum
Mar 2023
-303.20M
Average
-1.753B
Median
Cash from Financing (Quarterly) Benchmarks
| Johnson & Johnson | -9.882B |
| Eli Lilly and Co | 211.30M |
| Merck & Co Inc | -2.425B |
| Regeneron Pharmaceuticals Inc | -634.00M |
| Viking Therapeutics Inc | 2.522M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 3.571B |
| Cash from Investing (Quarterly) | -210.00M |
| Free Cash Flow | 6.283B |
| Free Cash Flow Per Share (Quarterly) | 6.114 |
| Free Cash Flow to Equity (Quarterly) | 5.561B |
| Free Cash Flow to Firm (Quarterly) | 4.022B |
| Free Cash Flow Yield | 3.96% |